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Abstract
Introduction: Mortality among HIV-positive adults awaiting antiretroviral therapy (ART) has previously been found to be high.
Here, we compare adolescent pre-ARTmortality to that of adults in a public sector HIV care programme in Bulawayo, Zimbabwe.
Methods: In this retrospective cohort study, we compared adolescent pre-ART outcomes with those of adults enrolled for HIV
care in the same clinic. Adolescents were defined as those aged 1019 at the time of registration. Comparisons of means
and proportions were carried out using two-tailed sample t-tests and chi-square tests respectively, for normally distributed data,
and the MannWhitney U-tests for non-normally distributed data. Loss to follow-up (LTFU) was defined as missing a scheduled
appointment by three or more months.
Results: Between 2004 and 2010, 1382 of 1628 adolescents and 7557 of 11,106 adults who registered for HIV care met the
eligibility criteria for ART. Adolescents registered at a more advanced disease stage than did adults (83% vs. 73% WHO stage III/
IV, respectively, pB0.001), and the median time to ART initiation was longer for adolescents than for adults [21 (1055) days
vs. 15 (742) days, pB0.001]. Among the 138 adolescents and 942 adults who never commenced ART, 39 (28%) of adolescents
and 135 (14%) of adults died, the remainder being LTFU. Mortality among treatment-eligible adolescents awaiting ART was
significantly higher than among adults (3% vs. 1.8%, respectively, p0.004).
Conclusions: Adolescents present to ART services at a later clinical stage than adults and are at an increased risk of death prior to
commencing ART. Improved and innovative HIV case-finding approaches and emphasis on prompt ART initiation in adolescents
are urgently needed. Following registration, defaulter tracing should be used, whether or not ART has been commenced.
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Introduction
There has been a rapid and substantial scale up of antire-
troviral therapy (ART) provision in sub-Saharan Africa over the
past decade which has been accompanied by substantially
increased survival of HIV-positive individuals [1]. There has
been much focus in HIV programmes on outcomes among
those who start ART, but HIV-positive individuals awaiting
initiation of ART have been largely overlooked [2,3]. Manage-
ment of HIV-positive individuals in the pre-ART period should
include regular clinical and CD4 count monitoring and provision
of cotrimoxazole prophylaxis. Mortality and loss to follow-up
(LTFU) in this period can be high but individuals defaulting
from services at the pre-ART stage are often not followed
up, unlike among those missing clinic appointments after
commencing ART [37].
It has been recognized in recent years that many children
with vertically acquired HIV infection in countries with gen-
eralized epidemics are entering adolescence undiagnosed [8].
Delayed presentation of these children to healthcare services
has been cited as one reason why mortality is generally the
highest in the first fewmonths following initiation [9]. Delayed
diagnosis is also associated with chronic complications such as
growth failure, neurocognitive impairment, and lung and
cardiac disease [10,11]. Further, avoidable delays between
registration and the administration of ART are likely to be
critically important [5,12,13]. In most cases, there is a prereq-
uisite period of counselling before ART is initiated which can
introduce an additional delay in commencing ART, particularly
where coordination within clinical services is lacking [5]. Older
children and adolescents may be at higher risk of mortality
because of the longer duration of having lived with untreated
HIV infection and are less able to afford further delays before
commencing treatment [14,15].
We conducted a retrospective cohort study to investigate
retention in care and mortality in the pre-ART period, as well
as factors associated with early programme mortality among
adolescents and adults registered in a large public sector HIV
care programme in Zimbabwe.
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Methods
Study setting and participants
Bulawayo, Zimbabwe’s second most populous city is located
in the southwest of the country and is home to 680,000
people (Population Statistics Office December 2010). The
Mpilo ART Clinic in Bulawayo was one of the first public
sector HIV care services to be established in Zimbabwe and
has provided ART since 2004, accumulating one of the
nation’s largest patient cohorts. Mpilo Clinic was the only
provider of paediatric and adolescent ART in Bulawayo
during the study period (2004 to 2010). Patients enrolling for
care had usually undergone HIV testing at an inpatient or
outpatient department of Mpilo hospital. HIV testing was
also available in primary care clinics within Bulawayo, and
in a variety of freestanding voluntary counselling and testing
(VCT) facilities. Throughout the study period, HIV care at
Mpilo was provided by the public sector in partnership with
Me´decins Sans Frontie`res (MSF) who supported staffing,
service development, and monitoring and evaluation. Volun-
teers were trained in defaulter tracing which aimed to bring
defaulters back into care with those who carried out this
work receiving incentives from a partner organization. Both
telephone follow-up and home visits were used, with all
those missing a visit by two or more months being eligi-
ble for defaulter tracing. Defaulter tracing focussed mainly
on those who had commenced ART rather than pre-ART
patients.
Eligible patients were adults and adolescents who enrolled
for HIV care between April 2004 and December 2010 at the
clinic. Age was defined from the date of an individual’s
first visit to the clinic. In line with the WHO definition, an
adolescent was defined as someone aged ]10 and B19.
Analyses included both treatment naı¨ve patients and those
with a history of having been on ART prior to enrolment.
The pre-ART period was defined as the period between
registration and initiation of ART. Individuals who missed
a scheduled appointment by three months or more were
classified as LTFU. In line with the national guidelines, ART
eligibility was met if an individual had a CD4 count less than
200 cells/mm3 and/or a WHO Stage III or IV illness.
Data collection
Since the clinic’s inception in 2004, details of all patients
have been systematically entered into an Access database
using software called FUCHIA (Epicentre, Paris, France). This
database is routinely updated during each patient follow-up
visit and includes details of anthropometric measures, CD4
counts, drug regimen details and treatment outcomes. This
database provided data on age, sex, date of commencing ART,
drug regimen, dates of clinic attendance, WHO clinical stage,
CD4 count and other laboratory recordings. LTFU status was
updated on an ongoing basis, allowing reclassification of
patients who returned to the clinic after a period of absence.
Mortality data were obtained through systematic tracing of
defaulters, as well as from community reporting and an
ongoing death register review.The last date for data collection
was 31 December 2010.
Statistical analysis of data
All statistical analyses were carried out using STATA version
10 (Stata-Corp, TX, USA). Comparisons of means and propor-
tions were carried out using two-tailed sample t-tests and chi-
square tests respectively for normally distributed data. The
Mann-Whitney U-test was used for the analysis of non-normally
distributed data. To assess the impact of delayed initiation on
mortality, a metric we refer to as ‘‘early programme mortality’’
was constructed, defined as any death (pre- or post-ART) occur-
ring within 12 months of registration among patients eligible for
ART at registration.We used linear regression to analyze secular
trends in early programme mortality over time; the dependent
variable being early programme mortality and the independent
variable being year of ART initiation. We performed a survival
analysis comparing time to event between groups using the log
rank test to establish if observed differences were statistically
significant.
Ethical considerations
Only routine data, collected for patient management and
programme monitoring were used. Individual consent to
use clinical data was not obtained. Patient confidentiality
was preserved by not extracting personal information which
could directly identify patients and records were anonymized
to maintain patient confidentiality. Ethical approval for this
study was obtained from the Mpilo Hospital Ethical Review
Board, who was informed that individual consent was not
obtained for reasons of feasibility as outlined above.
Results
Demographic and registration information was missing for
167 records. During the study period, 1973 adolescents and
11,106 adults completed initial registration at the clinic, of
whom 345 adolescents and 2056 adults had insufficient data
at registration to determine ART eligibility; these records
were excluded from analysis. This equated to 3519 person-
years (pyrs) of follow-up in adolescents and 20,458 in adults.
There was no difference in the hazard of mortality following
registration, comparing those excluded from analysis with
those included (p0.37, log rank).
Of the 1628 adolescents and 9050 adults included in
the analysis, 1382 (85%) adolescents and 7557 (84%) adults
satisfied ART eligibility criteria at enrolment. Between 2004
and 2010, the number of treatment-eligible adolescents
registering for HIV care increased four-fold, compared to a
less than two-fold increase in the corresponding number of
adult registrations (Figure 1).
Characteristics at registration into care
Among adults who registered for care, more than two-thirds
were female, but there was no difference by sex among
adolescents registering for HIV care. The median age at regis-
tration was 13.1 [interquartile range (IQR) 11.415.2] years
for adolescents and 36.6 (IQR 31.043.6) years for adults
(Table 1). The vast majority (95%) of adolescents were
assessed by clinicians to have been vertically infected based
on history of parental death or HIV status, self-report of sexual
debut, or blood transfusions and clinical history; although
it is possible that we may have underestimated the propor-
tion who were horizontally infected due to social desirability
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bias affecting responses to questions related to mode of
transmission.
Most adolescents underwent HIV testing following an HIV-
associated illness, with far fewer accessing HIV testing through
VCT services compared to adults (3.3% vs. 18.2%, pB0.001)
(Table 1). Adolescents presented at a more advanced WHO
disease stage than adults, with 83% of adolescents presenting
with WHO Stage III or IV disease, compared to 73% of adults
(pB0.001). A history of pulmonary TB, bacterial pneumonia
and anaemia was also significantly more common among
adolescents. However, adolescents had a higher median CD4
count at the time of registration compared to adults (210 vs.
162 cells/mm3, pB0.001). Adults were more likely to have
had prior exposure to ART than adolescents (15.7% vs. 5.4%,
pB0.001).
Pre-ART LTFU and mortality
Among those eligible for ART, 138 adolescents and 942 adults
had no record of ever initiating treatment. Of these, 39 (28%)
adolescents and 135 (14%) adults were known to have
died before starting ART, and the remainder did not start
treatment because they were LTFU. The mortality rate among
treatment-eligible adolescents who did not commence ART was
29.0 per 100 pyrs [95% confidence interval (CI): 21.139.6],
significantly higher than that among adults who did not
commence treatment (8.0 per 100 pyrs; 95% CI: 6.89.0),
(pB0.005). Following registration, treatment-eligible adoles-
cents waited significantly longer than adults to commence
ART, with the median time to ART initiation being 21 (1055)
days in adolescents vs. 15 (742) days in adults, pB0.001).
Early programme mortality among adolescents and adults
declined over time (univariate linear regression of year of
registration against early programme mortality, p0.006 and
p0.048, respectively) but fell more sharply in adults, and
mortality rates remained generally higher among adolescents
than in adults each calendar year (Table 2).
Discussion
The main finding of this study was that HIV-positive adoles-
cents are at a significantly higher risk of death than adults
while awaiting commencement of ART. This is likely explained
by the fact that adolescents registered at a more advanced
stage of HIV infection than did adults. The vast majority of
adolescents had evidence supporting vertical infection. Most
had been diagnosed recently and had no history of prior ART
use. The fact that they were only diagnosed in adolescence
implies a delay in diagnosis of over a decade and highlights
the inadequacies of current HIV case-finding strategies for
children. Over the study period, VCT services were scaled
up, enabling earlier diagnosis of HIV infection. However, these
services were available almost exclusively for adults, with
testing amongst adolescents primarily being carried out in
healthcare facilities and only after presentation with an illness
requiring hospitalization [14]. There was an additional delay in
commencing ART following registration, and this period was
significantly longer for adolescents than for adults, which may
reflect underpreparedness to initiate treatment as well as
factors such as reduced independent access to transport among
adolescents. Interestingly, adolescents had higherWHO disease
stage than adults but higher CD4 counts than adults at time
of registration. Current CD4 count thresholds for starting ART
among adolescents with vertically acquired HIV infection may
warrant being higher than those for adults [15,16].
Approximately one in ten ART-eligible individuals did not
commence ART and were LTFU. Although we cannot establish
the underlying reasons for this in our cohort, a study in
Figure 1. Numbers of adolescents and adults enrolling at Mpilo Clinic between 2004 and 2010 according to ART eligibility at time of
enrolment.
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Malawi within which similar numbers of eligible patients
failed to commence ART, found 58% of such patients to have
died [3,17]. Patients who do not die may return at a later
stage with more advanced disease whereas some may have
re-registered for HIV care elsewhere. Whilst most defaulter
tracing focuses on those who have initiated ART, these
findings underscore the importance of active follow-up for
patients in the pre-ART period. The importance of the pre-
ART period is highlighted here, as elsewhere, by the finding
that about 21% of all programmatic deaths in our cohort
occurred prior to the initiation of ART [1820]. As has been
pointed out by others, if pre-ART deaths are not included in
routine programme reporting, then overall programme out-
comes may appear misleadingly favourable [3,5]. Principally
this is because those with more advanced disease are more
likely to die in the pre-ART period, with those commencing
ART having a relative survival advantage. Thus, programmes
with many pre-ART deaths may record fewer early on-ART
deaths.
In an effort to assess the full programmatic impact of
delayed initiation, we examined mortality among ART-eligible
individuals within 12 months of registration, whether or not
they commenced ART (which we refer to as early programme
mortality). We believe that this provides a more useful indi-
cator of how well a programme manages patients from the
time they are registered, because it incorporates pre-ART
deaths as well as deaths among those newly commenced
on ART, which may be partly attributed to pre-ART delays.
It has been proposed that the pre-ART period be analyzed
at three stages [7].
Stage 1 is the period from a positive HIV test to receiving
the results of an initial CD4 count and being referred to either
pre-ART care or ART. Stage 2 is the pre-ART period, spanning
the period from enrolment for HIV care until ART eligibility.
Finally, Stage 3 is the time between an individual being
identified as eligible for ART and the commencement of
treatment. In this study, we have focussed on the third stage.
Overall LTFU and mortality across all three pre-ART stages is
likely to be considerably higher than is shown here.
To our knowledge, this is the first study to investigate
outcomes among adolescents awaiting ART. The large sample
size, long duration of follow-up, and the comprehensive
patient data collected throughout the study period are
strengths of this study. The limitations of this study are that
we do not have data on the reasons why individuals defaulted
from services prior to commencing ART. We cannot therefore
establish the relative contribution of death, relocation or
other factors (such as individual unwillingness to start). As
many of those LTFU before starting ART may have died, the
death rates among those not commencing ART are likely to
be underestimated [3].
In summary, our study showed that adolescents present to
HIV care services at a later clinical stage than adults and are
at higher risk of death than adults while awaiting initiation
of ART. Improved and innovative HIV case-finding approaches
and emphasis on prompt ART initiation in adolescents are
Table 1. Baseline characteristics of patients at registration at the Mpilo Clinic
Total Adults Adolescents p
Total number of registered patients 10,678 9050 1628 
Median age  years (IQR) 34.7
(27.041.9)
36.6
(31.043.6)
13.1
(11.415.2)

Male 35%
(3684/10,678)
32%
(2916/9050)
47%
(768/1628)
B0.001
Previous ARV history 14%
(1441/10,678)
15%
(1365/9050)
3%
(41/1623)
B0.001
VCT/self-referral 16%
(1696/10,645)
18%
(1642/9025)
3%
(54/1620)
B0.001
Percentage eligible to start ART 84%
(8939/10,678)
84%
(7557/9050)
85%
(1382/1628)
0.164
WHO Stage III/IV HIV disease 74%
(7526/10,161)
73%
(6316/8707)
83%
(1210/1457)
B0.001
Median CD4 count, cells/mm3 (IQR) 167
(75285)
(n6445)
162
(75275)
(n5535)
210
(85370)
(n910)
B0.001
CD4 count B200 cells/mm3 58%
(3736/6445)
60%
(3292/5535)
49%
(444/910)
B0.001
Haemoglobin B11 g/dl 85%
(2684/3144)
40%
(1072/2684)
47%
(216/460)
0.005
Pulmonary tuberculosis 10%
(1011/10,678)
9%
(836/9050)
11%
(175/1628)
0.055
Severe pneumonia 3%
(282/10,678)
2%
(220/9050)
4%
(62/1628)
B0.001
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urgently needed. Adolescents are poorly served by existing
case-finding services such as VCT, a situation likely to con-
tribute to their late presentation to services, in turn contrib-
uting to higher death rates among those awaiting ART. Earlier
identification of HIV-positive adolescents will require devel-
opment of new interventions given that current approaches
largely fail older children and adolescents. This must be
accompanied by linkage to care and timely initiation of ART
for treatment-eligible adolescents. The study highlights the
importance of the pre-ART period as a substantial contributor
to overall programme deaths. Social support models, such as
peer support clubs have generally focussed on those who
have initiated ART and in future should aim to include
individuals who are not yet eligible for ART. Pre-ARToutcomes
should be incorporated in routine HIV programme reporting,
and defaulter tracing activities should also include those who
have not commenced ART.
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